Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18481
- Registration Number
- NCT00825643
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00825253
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00824668
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2015-01-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT00822185
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 433
- Registration Number
- NCT00819741
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, China
Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT00818064
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 44
- Registration Number
- NCT00813020
Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT00806897
- Locations
- 🇱🇹
Novo Nordisk Investigational Site, Vilnius, Lithuania
Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4847
- Registration Number
- NCT00806936
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 526
- Registration Number
- NCT00806858
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath